- Home
- MGRX vs BGLC Comparison
MGRX vs BGLC Comparison
Compare MGRX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- BGLC
- Stock Information
- Founded
- MGRX 2021
- BGLC 2017
- Country
- MGRX United States
- BGLC Malaysia
- Employees
- MGRX N/A
- BGLC N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- BGLC Medical Specialities
- Sector
- MGRX Technology
- BGLC Health Care
- Exchange
- MGRX Nasdaq
- BGLC Nasdaq
- Market Cap
- MGRX 7.0M
- BGLC 7.6M
- IPO Year
- MGRX 2023
- BGLC N/A
- Fundamental
- Price
- MGRX $2.50
- BGLC $0.38
- Analyst Decision
- MGRX
- BGLC
- Analyst Count
- MGRX 0
- BGLC 0
- Target Price
- MGRX N/A
- BGLC N/A
- AVG Volume (30 Days)
- MGRX 1.0M
- BGLC 116.1K
- Earning Date
- MGRX 10-29-2024
- BGLC 11-20-2024
- Dividend Yield
- MGRX N/A
- BGLC N/A
- EPS Growth
- MGRX N/A
- BGLC N/A
- EPS
- MGRX N/A
- BGLC N/A
- Revenue
- MGRX $866,792.00
- BGLC $9,183,168.00
- Revenue This Year
- MGRX N/A
- BGLC N/A
- Revenue Next Year
- MGRX N/A
- BGLC N/A
- P/E Ratio
- MGRX N/A
- BGLC N/A
- Revenue Growth
- MGRX 245.48
- BGLC N/A
- 52 Week Low
- MGRX $2.15
- BGLC $0.31
- 52 Week High
- MGRX $16.80
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- MGRX 32.69
- BGLC 41.00
- Support Level
- MGRX $2.20
- BGLC $0.38
- Resistance Level
- MGRX $2.83
- BGLC $0.49
- Average True Range (ATR)
- MGRX 0.41
- BGLC 0.02
- MACD
- MGRX -0.06
- BGLC -0.00
- Stochastic Oscillator
- MGRX 8.44
- BGLC 32.66
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.